Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of bimekizumab in active ankylosing spondylitis has completed with results posted on 2024-10-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-10